Special ReportsAll NewsFDA BriefsOncology IconsThe Targeted PulseVoices from the Field
Conference CoverageConference ListingData Dialogue with the Oncology Brothers
All VideosCase-Based Peer PerspectivesEvolving Paradigms in OncologyExpert Perspective Virtual Tumor BoardInterviewsInvestigator PerspectivesMedical World NewsPersonalized MedicinePivotal Practice Views with the Oncology BrothersPodcastsSpeaking Out
All PublicationsEvolving ParadigmsPeers & Perspectives in OncologyTargeted Therapies in Oncology
CASE-BASED ROUNDTABLEPARTNERS
CME/CEClinical TrialsEventsPrecision Medicine PerspectivesPress ReleasesSponsored ContentTreatment Resources
SUBSCRIBE
BRAIN CANCER
BREAST CANCERBREAST CANCER
GENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERS
GENOMIC TESTINGGENOMIC TESTING
GI CANCERSGI CANCERSGI CANCERSGI CANCERSGI CANCERS
GYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERS
HEAD & NECK CANCERS
HEMATOLOGYHEMATOLOGY
IMMUNOTHERAPYIMMUNOTHERAPY
LEUKEMIASLEUKEMIASLEUKEMIASLEUKEMIAS
LUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCER
LYMPHOMASLYMPHOMASLYMPHOMASLYMPHOMAS
MPNs
MULTIPLE MYELOMA
NTRK GENE FUSIONS
SARCOMA
SKIN CANCERSSKIN CANCERS
THYROID CANCERS
Spotlight -
  • Biomarker-Driven Lung Cancer
  • GIST
  • HER2 Breast Cancer
  • Chronic Lymphocytic Leukemia
  • Small Cell Lung Cancer
  • Renal Cell Carcinoma
BRAIN CANCER
BREAST CANCERBREAST CANCER
GENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERS
GENOMIC TESTINGGENOMIC TESTING
GI CANCERSGI CANCERSGI CANCERSGI CANCERSGI CANCERS
GYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERS
HEAD & NECK CANCERS
HEMATOLOGYHEMATOLOGY
IMMUNOTHERAPYIMMUNOTHERAPY
LEUKEMIASLEUKEMIASLEUKEMIASLEUKEMIAS
LUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCER
LYMPHOMASLYMPHOMASLYMPHOMASLYMPHOMAS
MPNs
MULTIPLE MYELOMA
NTRK GENE FUSIONS
SARCOMA
SKIN CANCERSSKIN CANCERS
THYROID CANCERS
    • CASE-BASED ROUNDTABLE
    • PARTNERS
    • SUBSCRIBE
Advertisement

A 69-Year-Old Man With Advanced Castrate-Resistant Prostate Cancer

home / case-based-peer-perspectives / a-69-year-old-man-with-advanced-castrate-resistant-prostate-cancer

Jorge Garcia, MD, FACP, provides insight on the case of a 69-year-old man with mCRPC and assesses the classes of agents currently available as treatment options.

Case Overview: 69-Year-Old Man With Advanced CRPC

EP. 1: Case Overview: 69-Year-Old Man With Advanced CRPC

Jorge A. Garcia, MD, FACP
May 19th 2020

Watch

Standard of Care for mCRPC

EP. 2: Standard of Care for mCRPC

Jorge A. Garcia, MD, FACP
May 19th 2020

Watch

Therapeutic Options for mCRPC

EP. 3: Therapeutic Options for mCRPC

Jorge A. Garcia, MD, FACP
May 19th 2020

Watch

Approaching Therapy for mCRPC

EP. 4: Approaching Therapy for mCRPC

Jorge A. Garcia, MD, FACP
May 19th 2020

Watch

Management of mCRPC: Radium-223

EP. 5: Management of mCRPC: Radium-223

Jorge A. Garcia, MD, FACP
May 19th 2020

Watch

Radium 223: Counseling Patients With mCRPC

EP. 6: Radium 223: Counseling Patients With mCRPC

Jorge A. Garcia, MD, FACP
May 19th 2020

Watch

Combination of Radium-223 With Other Novel Agents in mCRPC

EP. 7: Combination of Radium-223 With Other Novel Agents in mCRPC

Jorge A. Garcia, MD, FACP
May 19th 2020

Watch

Importance of Bone Health Agents in mCRPC Management

EP. 8: Importance of Bone Health Agents in mCRPC Management

Jorge A. Garcia, MD, FACP
May 19th 2020

Watch

Role of Multidisciplinary Management in mCRPC

EP. 9: Role of Multidisciplinary Management in mCRPC

Jorge A. Garcia, MD, FACP
May 19th 2020

Watch

About Us
Advertise
Contact Us
CureToday.com
CancerNetwork.com
OncLive.com
OncNursingNews.com
Do Not Sell My Information
Privacy
Terms & Conditions
Editorial Board
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.